Pathophysiology and new therapeutic approaches in inflammatory bowel disease

Israel Medical Association Journal

Volumn 2, Issue 8, 2000, Pages 607-609

  Strul, H ^a   Arber, N ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Crohn's disease; Inflammatory bowel disease; New therapies; Pathophysiology; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; COTRIMOXAZOLE; CYCLOSPORIN; CYTOKINE; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; HEPARIN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTEGRIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; MERCAPTOPURINE; MESALAZINE; NATALIZUMAB; NITRIC OXIDE; STEROID; THALIDOMIDE; TRIMETHOPRIM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; COLON RESECTION; CROHN DISEASE; CYTOKINE RELEASE; DOSE RESPONSE; DRUG INHIBITION; DRUG PROTEIN BINDING; ENTERITIS; HUMAN; LAPAROSCOPIC SURGERY; LYMPHOCYTE PROLIFERATION; NEPHROTOXICITY; PATHOPHYSIOLOGY; RECEPTOR DOWN REGULATION; REMISSION; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 0033848546     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Treatment of Crohn's disease at the turn of the century
2. Therapy of inflammatory bowel disease
3. Lamina propria T-cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis
4. Tumor necrosis factor α antibody (Infliximab) therapy profoundly doon-regulates the inflammation in Crohn's ileocolitis
5. Crohn's disease is associated with novel polymorphisms in the 5'-flanking region of the tumor necrosis factor gene
6. Matrix metalloproteinase levels are elevated in inflammatory bowel disease
7. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease
8. Cyclosporin for severe ulcerative colitis
9. European trial of cyclosporine in chronic active Crohn's disease: A 12-month study. The European study group
10. Cyclosporine in an oral microemulsion as the initial treatment of corticoid-refractory ulcerative colitis
11. A short term study of chimeric monoclonal antibody (cA2) to tumor necrosis factor-α α for Crohn's disease
12. Endoasopic and histologic healing with Infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
13. New therapeutic approaches to Crohn's disease
14. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
15. An open-label pilot study of low dose Thalidomide in chronically active steroid-dependent Crohn's disease
16. The importance of early surgery in children with ulcerative colitis
17. Laparoscopic restorative proctocolectomy: Case-matched comparative study with open restorative proctocolectomy